| Literature DB >> 30400289 |
Agata Puzzovivo1, Francesco Monitillo2, Pietro Guida3, Marta Leone4, Caterina Rizzo5, Dario Grande6, Marco Matteo Ciccone7, Massimo Iacoviello8.
Abstract
AIM OF THE STUDY: In chronic heart failure (CHF) patients, renal congestion plays a key role in determining the progression of renal dysfunction and a worse prognosis. The aim of this study was to define the role of Doppler venous patterns reflecting renal congestion that predict heart failure progression.Entities:
Keywords: cardiorenal syndrome; congestion; heart failure; prognosis; renal Doppler
Year: 2018 PMID: 30400289 PMCID: PMC6306853 DOI: 10.3390/jcdd5040052
Source DB: PubMed Journal: J Cardiovasc Dev Dis ISSN: 2308-3425
Figure 1The different detectable renal venous patterns are presented. Pattern A was a flow pattern with normal velocity decrease of presystolic flow and biphasic pattern without interruption of telediastolic flow; Pattern B a continuous flow pattern with minimal fluctuations; Pattern C a pattern showing a short telediastolic interruption of forward flow or a short telediastolic reversal flow; Pattern D a flow characterized by a biphasic interruption or reversal flow during the same cardiac cycle; Pattern E a flow characterized by one forward and one reversal wave flow, i.e., monophasic intermittent pattern.
Baseline clinical characteristics of all patients and of patients divided according to the venous pattern.
| All Patients | Pattern | ||||||
|---|---|---|---|---|---|---|---|
| A | B | C | D | E | p | ||
| n: 338 | n: 83 | n: 92 | n: 82 | n: 41 | n: 40 | ||
| Age (years) | 64 ± 13 | 62 ± 14 | 61 ± 13 | 66 ± 13 | 66 ± 14 | 67 ± 12 | 0.016 |
| Males (%) | 81 | 83 | 84 | 85 | 76 | 70 | 0.221 |
| Ischemic cardiomyopathy (%) | 42 | 47 | 43 | 40 | 49 | 40 | 0.459 |
| History of hypertension (%) | 60 | 65 | 49 | 66 | 63 | 57 | 0.133 |
| Diabetes mellitus (%) | 30 | 33 | 25 | 33 | 27 | 35 | 0.673 |
| NYHA class | 2.4 ± 0.6 | 2.2 ± 0.6 | 2.2 ± 0.6 | 2.4 ± 0.5 | 2.6 ± 0.5 *,†,‡ | 2.8 ± 0.4 *,†,‡ | <0.001 |
| SBP (mm Hg) | 122 ± 16 | 126 ± 15 | 121 ± 14 | 124 ± 17 | 120 ± 17 | 113 ± 17 *,†,‡,# | <0.001 |
| Heart rate (beats per minute) | 69 ± 11 | 67 ± 9 | 67 ± 8 | 70 ± 13 | 71 ± 11 | 73 ± 10 †,‡ | 0.002 |
| GFR-EPI (mL/min/1.73 m2) | 72 ± 26 | 79 ± 23 | 79 ± 25 | 70 ± 25 | 63 ± 30 *,† | 57 ± 22 *,†,‡ | <0.001 |
| Hb (g/dL) | 13.6 ± 1.6 | 13.9 ± 1.5 | 14.0 ± 1.4 | 13.9 ± 1.6 | 12.6 ± 1.6 *,†,‡ | 12.6 ± 1.6 *,†,‡ | <0.001 |
| NT-proBNP (pg/mL) | 2311 ± 4844 | 827 ± 818 | 1171 ± 1490 | 2330 ± 2492 *,† | 4313 ± 3760 *,†,‡ | 5884 ± 11981 *,†,‡ | <0.001 |
| Microalbuminuria (%) | 27 | 18 | 16 | 28 | 61 *,†,‡ | 42 *,† | <0.001 |
| Ace-inhibitors/ARBs (%) | 81 | 93 | 88 | 74 * | 76 * | 60 *,† | <0.001 |
| Beta-blockers (%) | 97 | 99 | 98 | 98 | 98 | 88 *,†,‡ | 0.013 |
| Diuretics (%) | 93 | 88 | 88 | 96 *,† | 100 *,† | 100 *,† | <0.001 |
| Furosemide dose (mg/die) | 106 ± 131 | 68 ± 76 | 70 ± 72 | 111 ± 137 | 146 ± 179 *,† | 193 ± 176 *,†,‡,# | <0.001 |
| MRAs (%) | 72 | 76 | 71 | 71 | 66 | 87 | 0.110 |
| LVEF (%) | 33 ± 9 | 36 ± 7 | 33 ± 8 | 32 ± 8 | 29 ± 11 * | 31 ± 13 *,† | <0.001 |
| E/e’ ratio §§ | 14.8 ± 7.4 | 13.0 ± 6.0 | 12.1 ± 5.4 | 14.4 ± 6.2 | 14.3 ± 8.8 | 17.9 ± 7.4 *,†,‡,# | 0.014 |
| TAPSE (mm) | 19 ± 4 | 20 ± 4 | 19 ± 4 | 19 ± 5 | 17 ± 4 *,†,‡ | 16 ± 4 *,†,‡ | <0.001 |
| MR (a.u.) | 1.8 ± 0.9 | 1.5 ± 0.8 | 1.6 ± 0.8 | 1.8 ± 0.9 | 2.2 ± 0.9 *,†,‡ | 2.1 ± 1.1 *,† | <0.001 |
| TR (a.u.) | 1.8 ± 0.9 | 1.5 ± 0.7 | 1.4 ± 0.7 | 1.5 ± 0.7 | 2.7 ± 1.1 *,†,‡ | 2.8 ± 1.2 *,†,‡ | <0.001 |
| CVP > 5 mm Hg (%) | 26 | 5 | 2 | 30 *,† | 68 *,†,‡ | 70 *,†,‡ | <0.001 |
| RRI | 73 ± 8 | 71 ± 7 | 70 ± 7 | 74 ± 8 *,† | 78 ± 8 *,†,‡ | 77 ± 7 *,†,‡ | <0.001 |
* p < 0.05 vs. pattern A; † vs. pattern B; ‡ vs. Pattern C; vs. Pattern D at Newman-Keuls post-hoc analysis or Fisher test as appropriate. § Analysis for 307 patients without macroalbuminuria. §§ Available in 261 patients. Mean values ± SD or Percentage of patients. The table shoes ANOVA test for continuous variables F-Fisher tests for categorical variables. For NT-proBNP analyses were performed after logarithmic transformation. ARBs: Angiotensin II receptor blockers; a.u., arbitrary units; CVP, central venous pressure; GFR-EPI, glomerular filtration rate by EPI formula; MRA: Aldosteron receptor antagonist; LVEF, left ventricular ejection fraction; MR, mitral regurgitation; NYHA, New York Heart Association; NT-proBNP: brain natriuretic peptide. RRI, renal resistance index; TAPSE, peak of tricuspid annular plane systolic excursion; TR, tricuspid regurgitation.
Univariate analysis for primary end-point. For abbreviations see Table 1.
| Cox Univariate Analysis | ||
|---|---|---|
| HR (95% CI) |
| |
| Age | 1.02 (1.01–1.04) | 0.001 |
| Diabetes | 1.47 (1.03–2.12) | 0.036 |
| Ischemic aetiology | 1.52 (1.07–2.15) | 0.019 |
| Systolic arterial pressure | 0.98 (0.96–0.99) | <0.001 |
| ACE-I and/or ARBs | 0.33 (0.23–0.49) | <0.001 |
| Beta-blocker | 0.28 (0.14–0.57) | <0.001 |
| NYHA class III | 5.67 (3.82–8.39) | <0.001 |
| Heart rate > 70 | 1.64 (1.15–2.35) | 0.007 |
| LVEF < 30% | 3.27 (2.58–4.75) | <0.001 |
| Mitral regurgitation | 1.94 (1.62–2.33) | <0.001 |
| TAPSE < 15 | 2.91 (2.03–4.16) | <0.001 |
| Tricuspid regurgitation | 1.87 (1.59–2.21) | <0.001 |
| CVP > 5 mm Hg | 3.23 (2.26–4.64) | <0.001 |
| GFR-EPI | 0.98 (0.97–0.98) | <0.001 |
| Micro- or macroalbuminuria | 3.11 (2.19–4.43) | <0.001 |
| Hemoglobin | 0.74 (0.66–0.83) | <0.001 |
| NT-proBNP (×100) | 1.03 (1.02–1.03) | <0.001 |
| RRI > 75 | 2.99 (2.07–4.33) | <0.001 |
Reference model derived by using a forward stepwise Cox analysis where renal venous patterns categories have been included.
| Reference Model | Reference Model Plus Renal Venous Patterns | |||
|---|---|---|---|---|
| HR (95% CI) |
| HR (95% CI) |
| |
| NYHA class III | 3.01 (1.97–4.59) | <0.001 | 2.72 (1.76–4.20) | <0.001 |
| Heart rate > 70 | 1.69 (1.17–2.44) | 0.005 | 1.55 (1.07–2.27) | 0.005 |
| Mitral regurgitation | 1.29 (1.07–1.56) | 0.008 | 1.25 (1.04–1.52) | 0.008 |
| TAPSE < 15 | 1.59 (1.09–2.32) | 0.017 | 1.53 (1.05–2.25) | 0.017 |
| NT-proBNP (×100) | 1.020 (1.015–1.026) | <0.001 | 1.02 (1.012–1.023) | <0.001 |
| RRI > 75 | 1.92 (1.31–2.81) | 0.001 | 1.69 (1.14–2.50) | 0.001 |
| CRVP (type A or B) | 1.00 | - | ||
| MIRVP (type C) | 1.79 (1.09–2.97) | 0.023 | ||
| IRVP (type D or E) | 1.90 (1.16–3.12) | 0.011 | ||
CRVP: continuous renal venous flow pattern. IRVP: intermittent/reversal renal venous flow pattern. MIRVP: mild intermittent/reversal renal venous flow pattern. For the other abbreviations see Table 1.
Figure 2Kaplan Meier curves for the occurrence of death and/or hospitalization due to heart failure worsening in patients with continuous renal venous flow pattern (CRVP, i.e., Pattern A or B), mild intermittent/reversal renal venous flow pattern (MIRVP, i.e., Pattern C) and intermittent/reversal renal venous flow pattern (IRVP, i.e., Pattern D or E).